Pretreating mesenchymal stem cells with IL-6 regulates the inflammatory response of DSS-induced ulcerative colitis in rats

The immunomodulatory properties of mesenchymal stem cells (MSCs) have been broadly investigated in research on inflammatory diseases including ulcerative colitis. Treating MSCs with an inflammatory stimulus before transplantation is an adaptive strategy that helps MSCs survive in areas of inflammation and promotes the regulation of local immune responses. This study aimed to examine the effects of pretreating bone marrow MSCs (BMSCs) with Interleukin-6 (IL-6) on attenuation of dextran sulfate sodium (DSS)-induced ulcerative colitis in rats. Experimental ulcerative colitis was induced in Wistar rats by administering 2% DSS in their water for 7 days and normal water for the next 3 days. The experimental group received 1 x 106/0.4 ml of BMSCs that were treated with IL-6 for 24 h. Histological changes, colon length, and disease activity index were compared among groups, and the levels of TNF-alpha, IL-6, and IL-1 beta in homogenate supernatants were evaluated using ELISA. IL-6pretreated BMSCs significantly reduced the colonic damage score. The colon length shortened by 6.1 +/- 0.14 cm for the rats that received IL-6-pretreated BMSCs, whereas the control group rats' value was 3.8 +/- 0.14 cm on the 14th day. The levels of pro-inflammatory cytokines were significantly decreased in the colons of the IL-6pretreated BMSCs group compared with those of the control group (p < 0.05). This study revealed that IL-6pretreated BMSCs ameliorated DSS-induced colitis via local anti-inflammatory action and suggested that IL-6pretreated BMSCs are a promising therapeutic agent for ulcerative colitis treatment.